FACS analysis of GTG7 cells treated for 24 h with Rimonabant (5–20 μM) revealed that the compound significantly activates caspase-3 both in Wntlow differentiated tumor cells (in a more pronounced manner) and in Wnthigh CSCs, in a dose-dependent manner, starting from 10 μM (Figures 3A,B). This evidence concerns the gene CASP3 and neoplasm.